Clinical studies have shown that Desvenlafaxine does not have a clinically relevant effect on CYP2D6 (e.g., Desipramine, Atomoxetine, Dextromethorphan, Metoprolol, Nebivolol, Perphenazine, Tolterodine) metabolism at the dose of 100 mg daily. Reduce the dose of these substrates by one-half if co-administered with 400 mg of Desvenlafaxine. Avoid use of Desvenlafaxine with other Desvenlafaxine-containing products or Venlafaxine products. The concomitant use of Desvenlafaxine with other Desvenlafaxine-containing products or Venlafaxine will increase Desvenlafaxine blood levels and increase dose-related adverse reactions. Like CNS-acting drugs, patients should be advised to avoid alcohol consumption while taking Nevola®.